These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
700 related articles for article (PubMed ID: 1411618)
1. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma. Strauss G; Lund B; Hansen M; Hansen HH Gynecol Oncol; 1997 Jul; 66(1):66-70. PubMed ID: 9234923 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support. Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561 [TBL] [Abstract][Full Text] [Related]
4. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer. Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer. Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029 [TBL] [Abstract][Full Text] [Related]
7. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C; J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987 [TBL] [Abstract][Full Text] [Related]
8. Experience of a German multicenter study group with ifosfamide in small cell lung cancer. Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648 [TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
10. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
12. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial. Meerpohl HG; du Bois A; Luck HJ; Kühnle H; Möbus V; Kreienberg R; Bauknecht T; Köchli O; Bochtler H; Diergarten K Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-17-S2-22. PubMed ID: 9045330 [TBL] [Abstract][Full Text] [Related]
13. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
16. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. Crawford J; George M Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916 [TBL] [Abstract][Full Text] [Related]
17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222 [TBL] [Abstract][Full Text] [Related]